Cargando…

Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy

Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good prognostic capabilities for both hematological and solid malignancies. However, recent studies targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a therapeutic target. In order to examine the use o...

Descripción completa

Detalles Bibliográficos
Autores principales: Velazquez, Edwin J., Cress, Jordan D., Humpherys, Tyler B., Mortimer, Toni O., Bellini, David M., Skidmore, Jonathan R., Smith, Kathryn R., Robison, Richard A., Weber, Scott K., O’Neill, Kim L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893706/
https://www.ncbi.nlm.nih.gov/pubmed/35239730
http://dx.doi.org/10.1371/journal.pone.0264822
_version_ 1784662470113099776
author Velazquez, Edwin J.
Cress, Jordan D.
Humpherys, Tyler B.
Mortimer, Toni O.
Bellini, David M.
Skidmore, Jonathan R.
Smith, Kathryn R.
Robison, Richard A.
Weber, Scott K.
O’Neill, Kim L.
author_facet Velazquez, Edwin J.
Cress, Jordan D.
Humpherys, Tyler B.
Mortimer, Toni O.
Bellini, David M.
Skidmore, Jonathan R.
Smith, Kathryn R.
Robison, Richard A.
Weber, Scott K.
O’Neill, Kim L.
author_sort Velazquez, Edwin J.
collection PubMed
description Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good prognostic capabilities for both hematological and solid malignancies. However, recent studies targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a therapeutic target. In order to examine the use of TK1 as a therapeutic target, it is necessary to develop therapeutics specific for it. Single domain antibodies (sdAbs), represent an exciting approach for the development of immunotherapeutics due to their cost-effective production and higher tumor penetration than conventional antibodies. In this study, we isolated sdAb fragments specific to human TK1 from a human sdAb library. A total of 400 sdAbs were screened through 5 rounds of selection by monoclonal phage ELISA. The most sensitive sdAb fragments were selected as candidates for preclinical testing. The sdAb fragments showed specificity for human TK1 in phage ELISA, Western blot analysis and had an estimated limit of detection of 3.9 ng/ml for the antibody fragments 4-H-TK1_A1 and 4-H-TK1_D1. The antibody fragments were successfully expressed and used for detection of membrane associated TK1 (mTK1) through flow cytometry on cancer cells [lung (~95%), colon (~87%), breast (~53%)] and healthy human mononuclear cells (MNC). The most sensitive antibody fragments, 4-H-TK1_A1 and 4-H-TK1_D1 were fused to an engineered IgG1 Fc fragment. When added to cancer cells expressing mTK1 co-cultured with human MNCs, the anti-TK1-sdAb-IgG1_A1 and D1 were able to elicit a significant antibody-dependent cell-mediated cytotoxicity (ADCC) response against lung cancer cells compared to isotype controls (P<0.0267 and P<0.0265, respectively). To our knowledge this is the first time that the isolation and evaluation of human anti-TK1 single domain antibodies using phage display technology has been reported. The antibody fragments isolated here may represent a valuable resource for the detection and the targeting of TK1 on tumor cells.
format Online
Article
Text
id pubmed-8893706
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-88937062022-03-04 Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy Velazquez, Edwin J. Cress, Jordan D. Humpherys, Tyler B. Mortimer, Toni O. Bellini, David M. Skidmore, Jonathan R. Smith, Kathryn R. Robison, Richard A. Weber, Scott K. O’Neill, Kim L. PLoS One Research Article Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good prognostic capabilities for both hematological and solid malignancies. However, recent studies targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a therapeutic target. In order to examine the use of TK1 as a therapeutic target, it is necessary to develop therapeutics specific for it. Single domain antibodies (sdAbs), represent an exciting approach for the development of immunotherapeutics due to their cost-effective production and higher tumor penetration than conventional antibodies. In this study, we isolated sdAb fragments specific to human TK1 from a human sdAb library. A total of 400 sdAbs were screened through 5 rounds of selection by monoclonal phage ELISA. The most sensitive sdAb fragments were selected as candidates for preclinical testing. The sdAb fragments showed specificity for human TK1 in phage ELISA, Western blot analysis and had an estimated limit of detection of 3.9 ng/ml for the antibody fragments 4-H-TK1_A1 and 4-H-TK1_D1. The antibody fragments were successfully expressed and used for detection of membrane associated TK1 (mTK1) through flow cytometry on cancer cells [lung (~95%), colon (~87%), breast (~53%)] and healthy human mononuclear cells (MNC). The most sensitive antibody fragments, 4-H-TK1_A1 and 4-H-TK1_D1 were fused to an engineered IgG1 Fc fragment. When added to cancer cells expressing mTK1 co-cultured with human MNCs, the anti-TK1-sdAb-IgG1_A1 and D1 were able to elicit a significant antibody-dependent cell-mediated cytotoxicity (ADCC) response against lung cancer cells compared to isotype controls (P<0.0267 and P<0.0265, respectively). To our knowledge this is the first time that the isolation and evaluation of human anti-TK1 single domain antibodies using phage display technology has been reported. The antibody fragments isolated here may represent a valuable resource for the detection and the targeting of TK1 on tumor cells. Public Library of Science 2022-03-03 /pmc/articles/PMC8893706/ /pubmed/35239730 http://dx.doi.org/10.1371/journal.pone.0264822 Text en © 2022 Velazquez et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Velazquez, Edwin J.
Cress, Jordan D.
Humpherys, Tyler B.
Mortimer, Toni O.
Bellini, David M.
Skidmore, Jonathan R.
Smith, Kathryn R.
Robison, Richard A.
Weber, Scott K.
O’Neill, Kim L.
Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy
title Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy
title_full Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy
title_fullStr Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy
title_full_unstemmed Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy
title_short Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy
title_sort selection of human single domain antibodies (sdab) against thymidine kinase 1 and their incorporation into sdab-fc antibody constructs for potential use in cancer therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893706/
https://www.ncbi.nlm.nih.gov/pubmed/35239730
http://dx.doi.org/10.1371/journal.pone.0264822
work_keys_str_mv AT velazquezedwinj selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT cressjordand selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT humpherystylerb selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT mortimertonio selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT bellinidavidm selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT skidmorejonathanr selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT smithkathrynr selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT robisonricharda selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT weberscottk selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy
AT oneillkiml selectionofhumansingledomainantibodiessdabagainstthymidinekinase1andtheirincorporationintosdabfcantibodyconstructsforpotentialuseincancertherapy